Newsroom

Press & Media Resources

Logos, product photography, company facts, and lab documentation for your story about UVCeed.

As seen in
Newsweek USA Today Fortune AppleInsider
UVCeed portable UV-C device attached to a smartphone
7 Issued U.S. patents
99.99%* E. coli reduction in 24 s, lab tested
CES 2022 Public launch
Effingham, IL Headquarters

About UVCeed

UVCeed is a health technology company building portable UV-C treatment systems. Its patented technology pairs a handheld UV-C device with a smartphone app that guides coverage, measures delivered dose, and reports when the selected treatment target has been reached. In independent laboratory testing on clean, hard, nonporous test surfaces, UVCeed reduced S. aureus by 99.9% in 15 seconds and E. coli by 99.99% in 24 seconds, both at 12.7 cm. Results apply only to tested conditions.

The UVCeed device combines a UV-C LED with automatic exposure safeguards and app connectivity. The company's mission is to make dose-verified UV-C treatment available outside clinical settings, as an added step after visible soil is removed.

To make dose-verified UV-C treatment accessible outside clinical settings, creating safer environments where people can thrive.
Our mission

Fast facts

Co-Founder & CEO
Dr. Peter Bonutti, M.D.
Headquarters
Effingham, Illinois, USA
Category
Portable UV-C treatment system
Patents
7 issued U.S. patents, additional pending
Lab testing
Spectral Platforms, 2023
Healthcare use
Sarah Bush Lincoln Health Center

*In independent laboratory testing on clean, hard, nonporous test surfaces, UVCeed achieved 99.9–99.99% reduction of S. aureus, E. coli, and SARS-CoV-2 at defined times and distances. Results apply only to tested conditions. Results apply only to the tested organisms, surfaces, distances, and exposure times shown. Performance on other surfaces or at other distances has not been established.

Get in touch

Media contact

For press inquiries, interviews, product samples, or additional information, email us.

Press inquiries info@uvceed.com

We typically respond within 24 business hours.

For urgent media requests, include "URGENT" in your email subject line.

Dr. Peter Bonutti, M.D., Co-Founder and CEO of UVCeed
Available for interviews Request an interview